Lipid nanomaterials-based RNA therapy and cancer treatment.
10.1016/j.apsb.2022.10.004
- Author:
Xingcai ZHANG
1
;
Luo HAI
2
;
Yibo GAO
2
;
Guocan YU
3
;
Yingli SUN
4
Author Information
1. School of Engineering and Applied Sciences, Harvard University, Cambridge 02138, MA, USA.
2. Central Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen 518116, China.
3. Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology, Department of Chemistry, Tsinghua University, Beijing 100084, China.
4. Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
- Publication Type:Review
- Keywords:
Antisense oligonucleotides;
Cancer treatment;
Lipid nanoparticles;
Nanomedicine;
RNA therapy;
mRNA;
miRNA;
siRNA
- From:
Acta Pharmaceutica Sinica B
2023;13(3):903-915
- CountryChina
- Language:English
-
Abstract:
We summarize the most important advances in RNA delivery and nanomedicine. We describe lipid nanoparticle-based RNA therapeutics and the impacts on the development of novel drugs. The fundamental properties of the key RNA members are described. We introduced recent advances in the nanoparticles to deliver RNA to defined targets, with a focus on lipid nanoparticles (LNPs). We review recent advances in biomedical therapy based on RNA drug delivery and state-of-the-art RNA application platforms, including the treatment of different types of cancer. This review presents an overview of current LNPs based RNA therapies in cancer treatment and provides deep insight into the development of future nanomedicines sophisticatedly combining the unparalleled functions of RNA therapeutics and nanotechnology.
